LapWall releases its Q4 result on 6th of February. As the 2024 result is already largely known, our ...
SRV reports its Q4 figures on 6th of February. We expect slight improvement in adj.
Redeye updates its estimates and valuation on Embracer to reflect the Asmodee spin-off and the stron...
Q4 markerar en sval avslutning på året och Coor har flaggat för pressade marginaler mot bakgrund av ...
Solwers published a profit warning on Saturday 1 February, stating that Q4 2024 EBIT is close to ze...
Redeye updates its estimates and valuation following MedCap releasing its Q4 2024 report.
Redeye updates its estimates and valuation following Lifco releasing its Q4 2024 report.
Minor positive estimate revisions Margin expansion to be increasingly driven by scale Trading at '25...
Redeye is happy to see surprisingly upbeat numbers from Ependion.
Redeye changes its Base Case and forecasts following a strong end to a solid 2024 from Addnode.
Redeye publish a preview ahead of Northbaze's Q4 results, set to be released on Februaty 20.
Q4: -6% org. sales growth, 2% adj. EBITA growth, strong cash flow '25e-'26e adj.
Sales 0% and adj. EBIT +13% vs. ABGSCe Operating cash flow SEK 98m, vs ABGSCe SEK 6m Minor positive ...
Redeye shares its initial take on Kontigo Care’s Q4 2024 results, which showed sales and monthly rec...
Redeye comments on WntResearch’s conditional reverse acquisition of OPSY AB.
Vitrolife delivered a consecutive positive organic growth recovery with 6% organic growth in constan...
Redeye provides an initial comment on Addnode’s Q4 report, showing solid numbers in all three Divisi...
Redeye provides its initial take on MedCap’s Q4 2024 report, which came in broadly below our initial...
Redeye updates on Evolution following Q4-results which were in with our forecasts.
